TRAAC framework to improve regulatory acceptance and wider usability of tools and methods for safe innovation and sustainability of manufactured nanomaterials.


Journal

NanoImpact
ISSN: 2452-0748
Titre abrégé: NanoImpact
Pays: Netherlands
ID NLM: 101676795

Informations de publication

Date de publication:
04 2023
Historique:
received: 07 12 2022
revised: 24 03 2023
accepted: 03 04 2023
medline: 5 6 2023
pubmed: 12 4 2023
entrez: 11 4 2023
Statut: ppublish

Résumé

There has been an increasing use of advanced materials, particularly manufactured nanomaterials, in industrial applications and consumer products in the last two decades. It has instigated concerns about the sustainability, in particular, risks and uncertainties regarding the interactions of the manufactured nanomaterials with humans and the environment. Consequently, significant resources in Europe and beyond have been invested into the development of tools and methods to support risk mitigation and risk management, and thus facilitate the research and innovation process of manufactured nanomaterials. The level of risk analysis is increasing, including assessment of socio-economic impacts, and sustainability aspects, moving from a conventional risk-based approach to a wider safety-and-sustainability-by-design perspective. Despite these efforts on tools and methods development, the level of awareness and use of most of such tools and methods by stakeholders is still limited. Issues of regulatory compliance and acceptance, reliability and trust, user-friendliness and compatibility with the users' needs are some of the factors which have been traditionally known to hinder their widespread use. Therefore, a framework is presented to quantify the readiness of different tools and methods towards their wider regulatory acceptance and downstream use by different stakeholders. The framework diagnoses barriers which hinder regulatory acceptance and wider usability of a tool/method based on their Transparency, Reliability, Accessibility, Applicability and Completeness (TRAAC framework). Each TRAAC pillar consists of criteria which help in evaluating the overall quality of the tools and methods for their (i) compatibility with regulatory frameworks and (ii) usefulness and usability for end-users, through a calculated TRAAC score based on the assessment. Fourteen tools and methods were assessed using the TRAAC framework as proof-of-concept and for user variability testing. The results provide insights into any gaps, opportunities, and challenges in the context of each of the 5 pillars of the TRAAC framework. The framework could be, in principle, adapted and extended to the evaluation of other type of tools & methods, even beyond the case of nanomaterials.

Identifiants

pubmed: 37040858
pii: S2452-0748(23)00012-5
doi: 10.1016/j.impact.2023.100461
pmc: PMC10242441
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

100461

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Part Fibre Toxicol. 2017 Dec 19;14(1):54
pubmed: 29258600
Risk Anal. 2015 Feb;35(2):211-25
pubmed: 25616198
F1000Res. 2019 Aug 5;8:1353
pubmed: 31814965
CPT Pharmacometrics Syst Pharmacol. 2021 Aug;10(8):804-825
pubmed: 34102034
Sci Data. 2016 Mar 15;3:160018
pubmed: 26978244
Ann Work Expo Health. 2017 Oct 01;61(8):921-938
pubmed: 29028246
Regul Toxicol Pharmacol. 2013 Feb;65(1):79-86
pubmed: 23159863
Regul Toxicol Pharmacol. 2016 Oct;80:46-59
pubmed: 27255696
Nat Nanotechnol. 2018 Jul;13(7):537-543
pubmed: 29980781
EFSA J. 2018 Jul 04;16(7):e05327
pubmed: 32625968
Environ Int. 2016 Oct;95:36-53
pubmed: 27523267
Nanomaterials (Basel). 2019 May 04;9(5):
pubmed: 31060250
Nanotoxicology. 2012 Dec;6:880-98
pubmed: 22229953
Ann Occup Hyg. 2014 May;58(4):450-68
pubmed: 24449808
Nat Nanotechnol. 2021 Jun;16(6):644-654
pubmed: 34017099
Nat Nanotechnol. 2011 Feb;6(2):73-7
pubmed: 21151111
Ann Work Expo Health. 2020 Jun 24;64(5):479-489
pubmed: 32155241
Ann Work Expo Health. 2017 Aug 1;61(7):854-871
pubmed: 28810690
Ann Work Expo Health. 2020 Nov 16;64(9):944-958
pubmed: 32761049

Auteurs

Neeraj Shandilya (N)

TNO, Princetonlaan 6, 3584 CB Utrecht, Netherlands. Electronic address: neeraj.shandilya@tno.nl.

Marie-Sophie Barreau (MS)

TNO, Princetonlaan 6, 3584 CB Utrecht, Netherlands.

Blanca Suarez-Merino (B)

TEMAS Solutions GmbH, Lätteweg 5, 5212 Hausen, Switzerland.

Andrea Porcari (A)

Italian Association for Industrial Research, Airi, Viale Gorizia 25/C, 00198 Rome, Italy.

Daniela Pimponi (D)

Italian Association for Industrial Research, Airi, Viale Gorizia 25/C, 00198 Rome, Italy.

Keld Alstrup Jensen (KA)

National Research Centre for the Working Environment, 105 Lersø Parkallé, DK-2100 Copenhagen, Denmark.

Wouter Fransman (W)

TNO, Princetonlaan 6, 3584 CB Utrecht, Netherlands.

Remy Franken (R)

TNO, Princetonlaan 6, 3584 CB Utrecht, Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH